Results from a phase 3, multicenter, noninferiority study of ravulizumab (ALXN1210) versus eculizumab (ECU) in adult patients (PTS) with paroxysmal nocturnal hemoglobinuria (PNH) naive to complement inhibitors (CI)

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search DSpace


My Account